Real-world economic impact of onabotulinumtoxina in patients with chronic migraine

被引：0
|
作者：
Rothrock, J. F. [1 ]
Bloudek, L. M. [2 ]
Houle, T. T. [3 ]
Andress-Rothrock, D. [4 ]
Hanlon, C. [1 ]
Varon, S. F. [2 ]
机构：
[1] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[2] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[4] Univ Alabama Birmingham, Headache Treatment & Res Program, Birmingham, AL USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2013年 / 14卷
关键词：
Migraine; Chronic Migraine; Episodic Migraine; onabotulinumtoxinA; Urgent Care Center;
D O I：
10.1186/1129-2377-14-S1-P216
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Taoufik Alsaadi
    Suzan Noori
    Razmig Varakian
    Saly Youssef
    AbuBaker Almadani
    BMC Neurology, 22
  • [22] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Alsaadi, Taoufik
    Noori, Suzan
    Varakian, Razmig
    Youssef, Saly
    Almadani, AbuBaker
    BMC NEUROLOGY, 2022, 22 (01)
  • [23] Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies
    Schwedt, Todd J.
    Lee, Jae
    Knievel, Kerry
    McVige, Jennifer
    Wang, Weiying
    Wu, Zheng
    Gillard, Patrick
    Shah, Darshini
    Blumenfeld, Andrew M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (10) : 1119 - 1128
  • [24] Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal
    Andreou, A. P.
    Trimboli, M.
    Al-Kaisy, A.
    Murphy, M.
    Palmisani, S.
    Fenech, C.
    Smith, T.
    Lambru, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (08) : 1069 - +
  • [25] Insights Into the Mechanism of OnabotulinumtoxinA in Chronic Migraine
    Durham, Paul L.
    Cady, Roger
    HEADACHE, 2011, 51 (10): : 1573 - 1577
  • [26] Real-world onabotulinumtoxinA treatment patterns in patients with overactive bladder
    Chughtai, Bilal
    Ricker, Christine N.
    Boldt, Ryan J.
    Elterman, Dean
    NEUROUROLOGY AND URODYNAMICS, 2024, 43 (02) : 396 - 406
  • [27] Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Claims Analysis Study
    Schwedt, Todd J.
    Lee, Jae
    Knievel, Kerry
    McVige, Jennifer
    Wang, Weiying
    Wu, Zheng
    Gillard, Patrick
    Shah, Darshini
    Blumenfeld, Andrew M.
    TOXICON, 2022, 214 : S68 - S69
  • [28] OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine
    Cernuda-Morollon, Eva
    Ramon, Cesar
    Martinez-Camblor, Pablo
    Serrano-Pertierra, Esther
    Larrosa, Davinia
    Pascual, Julio
    PAIN, 2015, 156 (05) : 820 - 824
  • [29] Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
    Gomez-Dabo, Laura
    Caronna, Edoardo
    Mas-de-les-Valls, Rut
    Gallardo, Victor J.
    Alpuente, Alicia
    Torres-Ferrus, Marta
    Pozo-Rosich, Patricia
    TOXINS, 2024, 16 (05)
  • [30] Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study
    Gladstone, Jonathan
    Chhibber, Sameer
    Minhas, Jagdeep
    Neish, Calum S.
    Power, G. Sarah
    Lan, Zhiyi
    Rochdi, Driss
    Lanthier-Martel, Jessica
    Bastien, Natacha
    HEADACHE, 2022, 62 (01): : 78 - 88
12345